Orthofix and MTF Biologics Expand Partnership Agreement

By Julie A. Vetalice

Orthofix and MTF Biologics Expand Partnership Agreement

Orthofix Medical renewed and expanded its partnership agreement with MTF Biologics. The collaboration extends Orthofix’s exclusive marketing rights to the Trinity™ allograft line through 2032 and includes an expansion agreement to develop a demineralized bone matrix (DBM) that Orthofix will market under the Legacy™ brand name.

Legacy DBM will complement Orthofix products such as FiberFuse™ Advanced and FiberFuse Strip, both also provided by MTF Biologics. A demineralized cortical bone powder with a sodium hyaluronate carrier, Legacy DBM will be applicable in spine and orthopedic procedures. Product launch is slated for 3Q22.

“Together Orthofix and MTF Biologics have a long history of bringing advanced biologic solutions to the market, with more than 350,000 patients receiving their Trinity allografts,” said Orthofix President of Global Spine Kevin Kenny. “This agreement solidifies our partnership with MTF Biologics as the sole provider of MTF allograft offerings. The addition of the Legacy demineralized bone line will expand our biologic portfolio, increasing the options available and offering a value solution for our customers and their patients.”

Source: Orthofix

Product Labels: Bone Graft Materials/DBM